Rapid and stable mobilization of CD8<sup>+</sup> T cells by SARS-CoV-2 mRNA vaccine.

Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, Wild K, Basho K, Marinescu MS, Fuchs J, Topfstedt F, Janda A, Sogukpinar O, Hilger H, Stete K, Emmerich F, Bengsch B, Waller CF, Rieg S, Sagar, Boettler T, Zoldan K, Kochs G, Schwemmle M, Rizzi M, Thimme R, Neumann-Haefelin C, Hofmann M. · 2021

Read Rapid and stable mobilization of CD8<sup>+</sup> T cells by SARS-CoV-2 mRNA vaccine. by Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, Wild K, Basho K, Marinescu MS, Fuchs J, Topfstedt F, Janda A, Sogukpinar O, Hilger H, Stete K, Emmerich F, Bengsch B, Waller CF, Rieg S, Sagar, Boettler T, Zoldan K, Kochs G, Schwemmle M, Rizzi M, Thimme R, Neumann-Haefelin C, Hofmann M. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8426185.txt.

Introduction

Oberhardt and co-authors track CD8 T cells raised by the BNT162b2 mRNA vaccine. Protection from severe disease starts about ten days after the first dose. At that point, neutralizing antibodies are still hard to find. T cells may carry the early defense.

A strong, stable CD8 T cell response appeared one week after the first dose. That was before CD4 T cells and antibodies matured. The booster dose expanded the pool into highly developed effector cells. Memory precursor cells were not harmed by the boost. Vaccine-raised early memory cells worked as well as those from natural infection. Their subset mix, though, differed from infection.

Catalog record

CREATOROberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, Wild K, Basho K, Marinescu MS, Fuchs J, Topfstedt F, Janda A, Sogukpinar O, Hilger H, Stete K, Emmerich F, Bengsch B, Waller CF, Rieg S, Sagar, Boettler T, Zoldan K, Kochs G, Schwemmle M, Rizzi M, Thimme R, Neumann-Haefelin C, Hofmann M.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8426185

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine By Valerie Oberhardt, Hendrik Luxenburger, Janine Kemming, Isabel Schulien, Kevin Ciminski, Sebastian Giese, Benedikt Csernalabics, Julia Lang-Meli, Iga Janowska, Julian Staniek, Katharina Wild, Kristi Basho Published in: Nature DOI: 10.1038/s41586-021-03841-4 ABSTRACT SARS-CoV-2 spike mRNA vaccines1–3 mediate protection from severe disease as early as ten days after prime vaccination3, when neutralizing antibodies are hardly detectable4–6. Vaccine-induced CD8+ T cells may therefore be the main mediators of protection at this early stage7,8. The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. Here we show on a single-epitope level that a stable and fully functional CD8+ T cell response is vigorously mobilized one week after prime vaccination with bnt162b2, when circulating CD4+ T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion that generated highly differentiated effector CD8+ T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared with natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8+ T cells are important effector cells, are expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination. MAIN The current SARS-CoV-2 vaccination campaign provides the unique opportunity to gain important insights into human CD8+ T cell biology in the context of prime or boost mRNA vaccination. Initial data revealed that all arms of adaptive immunity such as neutralizing antibodies, virus-specific CD4+ T cells with T helper 1 (TH1) polarization and IFNγ-producing CD8+ T cells emerge after prime or boost vaccination4,5,9. The onset of mRNA vaccine-mediated protection has been observed as early as 10–12 days after the first dose3. During this early phase, T cells and spike-specific antibodies are detectable7,8, whereas neutralizing antibodies first appear after boost4–6,10,11. These observations point towards a key role of vaccine-induced T cells in early protection after prime vaccination. Previous studies focused on the analysis of the overall vaccine-elicited spike-reactive T cell response4,5,7,8,12; however, by this approach, the strength, dynamics and functional capacity are underestimated or even blurred in contrast to analyses performed at the single epitope level5. Here, we conducted continuous longitudinal analyses starting at baseline of prime vaccination until 3–4 months after boost on a single epitope level, to track the trajectories of bnt162b2 vaccine-elicited spike-specific CD8+ T cell responses in comparison to spike-specific CD4+ T cells, B cells, antibodies and their neutralizing activity. VACCINE-ELICITED CD8+ T CELLS We longitudinally collected peripheral blood mononuclear cells (PBMCs) and sera in 3–4-day intervals from 32 healthcare workers (Supplementary Table 1) that had not been previously infected with SARS-CoV-2, starting before prime until day 80–120 after boost (Extended Data Fig. 1a) and analysed the induction of spike-specific CD8+ T cells that target A*01/S865, A*02/S269 and A*03/S378 epitopes in 4–5 individuals each (Extended Data Fig. 1b). All three epitopes are not highly conserved between SARS-CoV-2 and SARS-CoV-1, MERS or common cold coronaviruses (Extended Data Fig. 1c). Thus, the detected spike-specific CD8+ T cells indeed reflect a response to vaccination. The epitopes are not affected by the sequence variations present in the variants of concern (VOC) alpha, beta, gamma and delta (Extended Data Fig. 1c). The tested A*01-, A*02- and A*03-restricted CD8+ T cells that are part of a broader spike-specific CD8+ T cell response, however, proved to be dominant when analysing responses that span the whole S protein (Extended Data Fig. 1d). Ex vivo frequencies of A*01/S865-, A*02/S269- and A*03/S378-specific CD8+ T cells were rather low after vaccination (Extended Data Fig. 2a). To increase the detection rate and to allow subsequent comprehensive profiling, we performed pMHCI-tetramer enrichment (Extended Data Fig. 2b). We detected a rapid and substantial induction of spike-specific CD8+ T cells that were present in 9 out of 13 tested donors already at days 6–8 and peaked in most donors 9–12 days post prime (dpp) (Fig. 1a). The strong CD8+ T cell activation was also reflected by high expression of CD38 and Ki-67 as early as days 6–8 in most cells (Fig. 1b, c and Extended Data Fig. 2c). Boost vaccination led to a further increase of CD8+ T cell frequencies that peaked 5–6 days post boost (dpb) with a subsequent slow contraction phase that reached nearly pre-boost frequencies at about 80–120 dpb (Fig. 1a). Post-boost and post-prime expansion were accompanied by effector T (Teff) cell differentiation (high expression of Ki-67, CD38, granzyme B, PD-1, CD39, T-BET and TOX) (Fig. 1b and Extended Data Fig. 2c–e). However, t-distributed stochastic neighbour embedding (t-SNE) analysis revealed that CD8+ Teff cells are qualitatively different at the peak expansion after boost (obtained at 5–6 dpb) compared with prime (obtained at 9–12 dpp) with a more consolidated cytotoxic effector cell phenotype (increased expression of T-BET, TOX and CD39) post boost (Extended Data Fig. 3a). This consolidated post-boost Teff cell response is further supported by diffusion map analysis (Fig. 1c and Extended Data Fig. 3b). Specifically, diffusion map embedding revealed a continuous relationship of the longitudinally collected spike-specific CD8+ T cells after prime (depicted in reddish colours)/boost (depicted in grey colours) indicating a directed trajectory of the Teff cell response. Along the trajectory, CD8+ T cells exhibited the highest expression of PD-1, TOX, T-BET and CD38 after boost indicating profound activation and progressing differentiation (Fig. 1c and Extended Data Fig. 3b). Of note, a single vaccine dose also induced boost expansion and strong activation but lower TOX expression (Extended Data Fig. 4a–c) of spike-specific CD8+ T cells in individuals who recovered from mild to moderate infection approximately 12 months before vaccination (Supplementary Table 1).Fig. 1Vaccine-elicited epitope-specific CD8+ T cells.a, Calculated ex vivo frequency indicated at baseline (BL), dpp and dpb for spike-specific CD8+ T cells. Detection limit: 5 × 10−6. b, Percentage of CD38, Ki-67 and T-BEThi expressing spike-specific non-naive CD8+ T cells. c, Diffusion map showing flow cytometry data for A*02/S269-specific CD8+ T cells in relation to dpp (shades of red) and dpb (shades of grey) in one individual. Expression levels of CD38, T-BET, TOX and BCL-2 are plotted on the diffusion map (blue denotes low expression; red denotes high expression). d, e, Calculated ex vivo frequencies of non-naive spike-specific CD8+ T cells expressing CD127 or TCF-1 for spike-specific CD8+ T cells. Line indicates median. P values determined by two-way ANOVA with main effects only comparing the effect of the different epitopes (Pe) and of time course (Pt:).Source data We also assessed the induction of spike-specific memory precursor CD8+ T cells that are characterized by CD127, BCL-2 and TCF-1 expression and are relevant for maintaining the CD8+ T cell response13,14. Roughly 20–30% of spike-specific CD8+ T cells expressed CD127 after prime followed by a transient reduction and subsequent strong increase after boost (Fig. 1d and Extended Data Fig. 4d). Expression dynamics of TCF-1 (Fig. 1e and Extended Data Fig. 4e) and BCL-2 (Extended Data Fig. 4f) were similar to CD127. However, the overall frequency of CD127+ (Fig. 1d) and TCF-1+ (Fig. 1e) spike-specific CD8+ T cells remained constant indicating a stable memory precursor pool induced already early after prime vaccination. Together, bnt162b2 vaccination

Read the complete text